SeveriDx
Unlock the Future: Timely deciphering of patients
suspected of acute respiratory infections.
Our novel biomarker is designed to inform clinicians
about high-risk patients to develop acute respiratory infections.
Respiratory infections in numbers
Respiratory infections are among the most deadly communicable diseases worldwide. According to WHO and CDC, influenza alone leads to millions of hospitalizations and hundreds of thousands of deaths annually.
MERS
2018-2018
Hospitalized
2.2 K
Deaths
858
SARS-CoV-2
2019-2024
Hospitalized
78 – 116 Mil
Deaths
7.1 Mil
Influenza
each year
Hospitalized
100 – 750 K
Deaths
4.9 – 51 K
RSV infections
each year
Hospitalized
100 – 320 K
Deaths
6 – 10 K
To foresee respiratory severity
before symptoms escalate.
Timely and accurate prediction of acute respiratory failure is crucial for clinicians to make informed decisions, especially in cases where the need for ICU-level care is uncertain.
SeveriDx, a spin-off from GeneSpector, offers an advanced diagnostic test to predict the severity of respiratory infections.
The SeveriDx (SDx) mission is to transform the future of respiratory infection management by providing an innovative tool that enables healthcare professionals, combined with standard clinical assessments, to reduce hospitalizations by identifying patients at risk of severe complications, optimizing treatment pathways, and monitoring therapy effectiveness.
SeveriDx in a nutshell
SeveriDx offers a groundbreaking In-vitro Diagnostic (IVD) Kit designed to predict the severity of respiratory infections. Our kit utilizes a universal prognostic biomarker to identify high-risk conditions.
Early detection of respiratory infection severity
A patented novel universal biomarker reflecting the acute inflammatory status
Non-invasive testing using nasal swabs
Rapid analysis with results in 90 minutes
Compatible with existing clinical workflows and infrastructure
The higher the value
─── the worse the health condition
A universal biomarker to identify individuals at high risk of severe health issues from any respiratory infection.
In conjunction with established risk factors, it provides a comprehensive framework for determining the most appropriate treatment strategies.
A specific biomarker that serves as a pivotal indicator to guide a decision-making process.
Our management team
SeveriDx benefits from the expertise of its founders and management team, including leaders from GeneSpector, the scientific advisory board of GeneSpector, and strategic partners such as Immunotech, Charles University, and SPADIA LAB. The team’s deep knowledge in diagnostics and healthcare ensures the successful execution of our business plan.
Katerina Solcova, PhD
CEO
Michal Pohludka, PhD
Execuvite Director
